Freed vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI medical scribe used by 20,000+ clinicians at $99/mo. $20M+ ARR. 32M+ patient visits transcribed. $30M Series A led by Sequoia Capital. Founded 2022, SF. Private.
About
Freed is an AI medical scribe founded in 2022 by CEO Erez Druk, headquartered in San Francisco. The platform listens to patient-clinician encounters and automatically generates structured clinical notes including SOAP notes, referral letters, patient instructions, and ICD-10/CPT billing codes. Priced at $99/month per clinician vs $25-50/hour for human scribes.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.